Drug Profile
GLPG 2851
Alternative Names: GLPG-2851Latest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Galapagos NV
- Developer AbbVie; Galapagos NV
- Class Antifibrotics; Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cystic fibrosis